An Anti–CLL-1 Antibody–Drug Conjugate for the Treatment of Acute Myeloid Leukemia
暂无分享,去创建一个
Genee Y. Lee | Cécile Chalouni | R. Vij | Vanessa L. Clark | Wei-Ching Liang | Yan Wu | J. Flygare | Thomas H. Pillow | J. Sadowsky | Geoffrey del Rosario | Shang‐Fan Yu | M. Schutten | A. Polson | S. Leong | B. Zheng | K. A. Poon | C. Chiu | A. Hendricks | W. Chu | Cecile Chalouni | Geoffrey Del Rosario
[1] F. Ravandi,et al. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. , 2018, Blood.
[2] K. Keeshan,et al. Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia. , 2017, Experimental Hematology.
[3] L. Anelli,et al. CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds? , 2017, Expert review of hematology.
[4] M. Subklewe,et al. Recent developments in immunotherapy of acute myeloid leukemia , 2017, Journal of Hematology & Oncology.
[5] C. Bloomfield,et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation , 2017, The New England journal of medicine.
[6] R. Gale,et al. Gemtuzumab ozogamicin in acute myeloid leukemia , 2017, Leukemia.
[7] I. Flinn,et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.
[8] J. Cortes,et al. Treatment of Relapsed/Refractory Acute Myeloid Leukemia , 2017, Current Treatment Options in Oncology.
[9] Jeffrey T. Lau,et al. Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody–Drug Conjugates with Self-Immolative Disulfide Linkers , 2017, Molecular Cancer Therapeutics.
[10] Genee Y. Lee,et al. An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia. , 2017, Blood.
[11] P. Jackson,et al. From Anthramycin to Pyrrolobenzodiazepine (PBD)‐Containing Antibody–Drug Conjugates (ADCs) , 2016, Angewandte Chemie.
[12] J. Flygare,et al. Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates , 2016, Chemical science.
[13] F. Ravandi,et al. Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML) , 2016 .
[14] E. Feldman,et al. ACUTE MYELOID LEUKEMIAS ( H ERBA , SECTION EDITOR ) Antibody-Based Treatment of Acute Myeloid Leukemia , 2016 .
[15] S. Mousa,et al. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1 , 2016, Oncotarget.
[16] Paul Polakis,et al. Antibody Drug Conjugates for Cancer Therapy , 2016, Pharmacological Reviews.
[17] D. Benjamin,et al. SGN-CD33A in Combination with Hypomethylating Agents Is Highly Efficacious in Preclinical Models of AML , 2015 .
[18] R. Soriano,et al. A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs , 2015, Clinical Cancer Research.
[19] T. Pabst,et al. Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia , 2014, PloS one.
[20] U. Testa,et al. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies , 2014, Biomarker Research.
[21] I. Bernstein,et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. , 2013, Blood.
[22] Laurent Ducry,et al. Antibody-Drug Conjugates , 2013, Methods in Molecular Biology.
[23] I. Bernstein,et al. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. , 2012, Blood.
[24] Gordon D. Brown,et al. Expression of the hMICL in acute myeloid leukemia—a highly reliable disease marker at diagnosis and during follow‐up , 2012, Cytometry. Part B, Clinical cytometry.
[25] J. Hartley,et al. DNA interstrand cross-linking and in vivo antitumor activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057 , 2012, Investigational New Drugs.
[26] A. Vekhoff,et al. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia , 2012, Investigational New Drugs.
[27] J. Hartley. The development of pyrrolobenzodiazepines as antitumour agents , 2011, Expert opinion on investigational drugs.
[28] T. Yamauchi,et al. Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses. , 2011, International journal of oncology.
[29] J. Berlin,et al. Phase I Pharmacokinetic and Pharmacodynamic Study of SJG-136, a Novel DNA Sequence Selective Minor Groove Cross-linking Agent, in Advanced Solid Tumors , 2011, Clinical Cancer Research.
[30] R. Begent,et al. Phase I Study of Sequence-Selective Minor Groove DNA Binding Agent SJG-136 in Patients with Advanced Solid Tumors , 2009, Clinical Cancer Research.
[31] M. Patnaik,et al. Anthracycline dose intensification in acute myeloid leukemia. , 2009, The New England journal of medicine.
[32] G. V. van Dongen,et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. , 2005, Blood.
[33] S. Gordon,et al. Human MICL (CLEC12A) is differentially glycosylated and is down‐regulated following cellular activation , 2006, European journal of immunology.
[34] Keiji Takamoto,et al. Radiolytic protein footprinting with mass spectrometry to probe the structure of macromolecular complexes. , 2006, Annual review of biophysics and biomolecular structure.
[35] H. Gundacker,et al. Age and acute myeloid leukemia. , 2006, Blood.
[36] T. Lister,et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. , 2005, Blood.
[37] G. Schuurhuis,et al. C-Type Lectin-Like Molecule-1 , 2004, Cancer Research.
[38] S. Gordon,et al. Identification and Characterization of a Novel Human Myeloid Inhibitory C-type Lectin-like Receptor (MICL) That Is Predominantly Expressed on Granulocytes and Monocytes* , 2004, Journal of Biological Chemistry.
[39] E. Estey. Therapeutic options for acute myelogenous leukemia , 2001, Cancer.